ORBIMED ADVISORS LLC bought PRLD

April 21, 2026 · Form 4 insider transaction

ORBIMED ADVISORS LLC bought 1,689,189 shares of Prelude Therapeutics Incorporated at $4.44 per share, a transaction worth $7.50M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
1,689,189
Price
$4.44
Total value
$7.50M
Role
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateApril 21, 2026
Filing dateApril 23, 2026
Shares owned after11,808,945
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

These securities were purchased in an underwritten public offering.; These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.; This report on Form 4 is filed by OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

View the original Form 4 on SEC EDGAR